Marjorie van de Stouwe, MD
Rheumatology · Rockville Centre, NYNPI 1962427138
Payments from drug & device makers
Across 395 payments — averaging $16.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- GSK$949
- Johnson & Johnson$803
- AstraZeneca$570
- Genentech USA, Inc.$305
- Novartis$266
- plus $2K from 19 others
What the payments were for
- Food & beverage$6,15393%
- Education$4327%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 135 | $2,010 |
| GSK | 47 | $949 |
| Johnson & Johnson | 54 | $803 |
| AstraZeneca | 31 | $570 |
| Genentech USA, Inc. | 18 | $305 |
| Novartis | 15 | $266 |
| UCB, Inc. | 16 | $249 |
| ANI Pharmaceuticals, Inc. | 8 | $222 |
| Mallinckrodt Enterprises LLC | 9 | $210 |
| Merck | 13 | $199 |
| Organon | 15 | $180 |
| E.r. Squibb & Sons, L.L.C. | 9 | $136 |
| Pfizer | 5 | $106 |
| Mallinckrodt Hospital Products Inc. | 3 | $77 |
| Endo Pharmaceuticals Inc. | 3 | $61 |
| Aurinia Pharma U.S., Inc. | 3 | $53 |
| Scilex Pharmaceuticals Inc. | 2 | $31 |
| Pacira Therapeutics, Inc. | 2 | $28 |
| Endo USA, Inc. | 1 | $24 |
| Radius Health, Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $20 |
| Boehringer Ingelheim | 1 | $19 |
| Bristol Myers Squibb | 1 | $18 |
| Bioventus LLC | 1 | $15 |
| AbbVie | 1 | $13 |
How this compares
$6,586 in reported general payments places this provider in the 60th percentile of 541 rheumatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MethotrexateMethotrexate Sodium | 86 | $2,788 |
| Duloxetine Hcl | 23 | $1,664 |
| Hydroxychloroquine Sulfate | 36 | $1,277 |
| Prednisone | 109 | $969 |
| Allopurinol | 45 | $582 |
| Gabapentin | 28 | $220 |
| Omeprazole | 14 | $91 |
| Folic Acid | 12 | $90 |
| Naproxen | 11 | $33 |
| Meloxicam | 19 | $20 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Rockville Centre
- Amit SaxenaNew York$6.7M
- Cynthia AranowManhasset$5.3M
- Richard FurieNew Hyde Park$4.3M
- Robert SpieraNew York$4.3M
- David GoddardBrooklyn$3.9M
- Laurie GlimcherNew York$3.9M
- Anca AskanaseNew York$3.5M
- Grace WrightNew York$3M
- Jose ScherNew York$2.7M
- Kostas BotsoglouCheektowaga$2.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.